Sitemap
- Patient Support
- Products
- Privacy Policy
- Terms & Conditions of Use
- Cookie Policy
- My Account
- Login
- Sitemap
- Campus MY Sanofi Terms of Use
- Campus MY Sanofi PDPN
- Search
-
Science
-
Cutting Edge Science
-
Cardiovascular
-
Hypertension
-
2022
-
2023
-
2024
- Effect of ARB-based therapy in hypertensive patients with hyperuricemia and microalbuminuria
- Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in patients with hypertension
- Self-reported single adherence question scored on a visual analogue scale predicts cardiovascular outcomes and mortality
- 2025
-
2022
-
Acute Coronary Syndrome
-
2022
-
2023
-
2024
-
2025
- ACS Management: Insights on Rare Cases and Emerging Predictors
- Clopidogrel: Rethinking Antiplatelet Strategies for Better Outcomes
- Optimizing Hypertension Management: Single-Pill Combinations and Key Insights for Better Outcomes
- Evolving Insights on DAPT and SAPT: Highlights From Recent Key Trials
- Dual Therapy, FCAPs, and Antiplatelets: Recent Evidence You Should Know
- Personalizing Cardiovascular Care in Asian Populations: Insights on Antiplatelet Safety & Lipid Risk
- Personalizing Antiplatelet Therapy: Insights for High-Risk PCI Patients
- Antiplatelet Therapy in ACS: Moving Beyond One-Size-Fits-All
- Comprehensive Insights into ACS: From Platelet Reactivity to Treatment Adherence
- Personalizing Antiplatelet Therapy in Complex PCI & High-Risk Coronary Interventions
- Evidence-Based Antiplatelet Selection in ACS patients
- P2Y12 inhibitors vs. NSAIDs : Latest Evidence for Optimal Antiplatelet Therapy
-
2022
-
Hypertension
- Immunology
- Neurology
- Rare Disease
- Vaccines
-
Cardiovascular
- Events
-
Cutting Edge Science
- Registration